Edwyn
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | $13,445 | $10,982 | $10,173 | $9,836 | $9,676 |
| Gross Profit | $11,639 | $8,872 | $7,895 | $7,302 | $7,366 |
| Operating Income | $4,550 | $2,841 | N/A | N/A | N/A |
| Net Income | $4,001 | $1,556 | $3,047 | $1,161 | $1,632 |
Over the past five years, BIOGEN INC. has experienced significant fluctuations in its revenue and profitability metrics, highlighting both operational challenges and potential strategic realignments. In 2020, the company posted its highest revenue at USD 13,444.6 million and robust gross profit of USD 11,639.4 million, with operating income registering at USD 4,550.1 million and net income at USD 4,000.6 million. However, by 2021, revenue declined by roughly 18% to USD 10,981.7 million, and gross profit fell to USD 8,872 million. Operating income also dropped significantly to USD 2,840.7 million. A dramatic swing is evident in net income, which plummeted by over 60% to USD 1,556.1 million relative to the prior year—a notable decline that suggests underlying pressures such as increased costs, R&D investments, or market headwinds impacting profitability. From 2022 onwards, revenue continued a gradual decline, reaching USD 9,675.9 million in 2024, while gross profits remained relatively stable in the latter years around the mid-7,300 million range. The operating income category, however, notably registered as zero from 2022 to 2024, raising questions about the company’s core operational efficiencies and portfolio profitability during that period. Meanwhile, net income rebounded to USD 3,046.9 million in 2022 before falling to USD 1,161.1 million in 2023 and slightly recovering to USD 1,632.2 million in 2024. Given the biotech sector’s competitive and innovative nature—often marked by high R&D expenditures and regulatory risks—these shifts reflect a transitional phase rather than definitive distress. Overall, while BIOGEN INC. appears to be grappling with declining revenue and margins, the resilience in its gross profit levels and partial net income recovery suggest that the company maintains a degree of financial sustainability amid industry volatility.
This analysis is for informational purposes only and does not constitute financial advice or recommendations for any investment decisions. Please consult with a qualified financial professional for personalized guidance.